Details of the Drug

General Information of Drug (ID: DMA7PEW)

Drug Name

Verapamil

Synonyms

Arpamyl; Calan; Calcan; Cordilox; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isotopin; Vasolan; Veracim; Verapamilo; Verapamilum; Veraptin; Verexamil; Bosoptin (TN); Calan (TN); D-365; Isoptin (TN); Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]; Verelan (TN); CP-16533-1; Covera-HS (TN); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; (+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Verapamil (Na-Ca chanel blocker)

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Approved	[1]
Atrial fibrillation	BC81.3	Approved	[1]
Classic phenylketonuria	N.A.	Approved	[1]
Hypertension	BA00-BA04	Approved	[2]
Malignant essential hypertension	BA00	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2/3	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

454.6

Logarithm of the Partition Coefficient (xlogp)

3.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 18 mL/min/kg [5]
Elimination: 1.5% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.8 hours [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.093% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.7 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.75 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Poisoning and toxicity	Not Available	CYP2D6	OTZJC802	[6]
Sudden cardiac death	Not Available	KCNQ1	OT8SPJNX	[6]
Sudden cardiac death	Not Available	SCN5A	OTGYZWR6	[6]
Sudden cardiac death	Not Available	KCNE1	OTZNQUW9	[6]
-----------

Chemical Identifiers

Formula: C27H38N2O4
IUPAC Name: 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
Canonical SMILES: CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
InChI: InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
InChIKey: SGTNSNPWRIOYBX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2520
ChEBI ID: CHEBI:77733
CAS Number: 52-53-9
DrugBank ID: DB00661
TTD ID: D0R0FE
VARIDT ID: DR00264
INTEDE ID: DR1681
ACDINA ID: D00726

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)	TT729IR	CAC1G_HUMAN	Blocker	[7]
HUMAN two pore channel subtype 2 (TPC2)	TTHQJ2Y	TPC2_HUMAN	Blocker	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance protein 3 (ABCB4)	DTZRMK5	MDR3_HUMAN	Substrate	[9]
Organic cation/carnitine transporter 1 (SLC22A4)	DT2EG60	S22A4_HUMAN	Substrate	[10]
Organic cation/carnitine transporter 2 (SLC22A5)	DT3HUVD	S22A5_HUMAN	Substrate	[11]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[12]
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[13]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[14]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[15]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[16]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[17]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[18]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[19]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[20]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[16]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[21]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[22]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[16]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-1A adrenergic receptor (ADRA1A)	OTUIWCL5	ADA1A_HUMAN	Protein Interaction/Cellular Processes	[23]
Alpha-1B adrenergic receptor (ADRA1B)	OTSAYAFD	ADA1B_HUMAN	Protein Interaction/Cellular Processes	[23]
Alpha-1D adrenergic receptor (ADRA1D)	OTW2CD1O	ADA1D_HUMAN	Protein Interaction/Cellular Processes	[23]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[24]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[24]
ATP-binding cassette sub-family C member 6 (ABCC6)	OTZT0LKT	MRP6_HUMAN	Gene/Protein Processing	[25]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[26]
Beta-1 adrenergic receptor (ADRB1)	OTQBWN4U	ADRB1_HUMAN	Drug Response	[27]
Calcium-activated potassium channel subunit beta-1 (KCNMB1)	OTO4KNJ4	KCMB1_HUMAN	Drug Response	[28]
Clusterin (CLU)	OTQGG0JM	CLUS_HUMAN	Gene/Protein Processing	[29]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Verapamil

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Acebutolol	DM0TI4U	Major	Increased risk of cardiac depression by the combination of Verapamil and Acebutolol.	Hypertension [BA00-BA04]	[30]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of Verapamil caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[31]
Penbutolol	DM4ES8F	Major	Increased risk of cardiac depression by the combination of Verapamil and Penbutolol.	Hypertension [BA00-BA04]	[30]
Nebivolol	DM7F1PA	Major	Increased risk of cardiac depression by the combination of Verapamil and Nebivolol.	Hypertension [BA00-BA04]	[30]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Verapamil caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[31]
Pindolol	DMD2NV7	Major	Increased risk of cardiac depression by the combination of Verapamil and Pindolol.	Hypertension [BA00-BA04]	[30]
-----------


⏷ Show the Full List of 6 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Verapamil (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Clindamycin	DM15HL8	Moderate	Increased plasma concentration of Verapamil and Clindamycin due to competitive binding of plasma proteins.	Acne vulgaris [ED80]	[32]
Repaglinide	DM5SXUV	Moderate	Decreased metabolism of Verapamil caused by Repaglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[33]
Ivosidenib	DM8S6T7	Major	Increased metabolism of Verapamil caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[34]
Midostaurin	DMI6E0R	Moderate	Decreased metabolism of Verapamil caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[35]
Daunorubicin	DMQUSBT	Moderate	Decreased clearance of Verapamil due to the transporter inhibition by Daunorubicin.	Acute myeloid leukaemia [2A60]	[36]
Gilteritinib	DMTI0ZO	Moderate	Decreased metabolism of Verapamil caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[37]
Ivabradine	DM0L594	Major	Decreased metabolism of Verapamil caused by Ivabradine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[37]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Verapamil caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[38]
Cilostazol	DMZMSCT	Major	Decreased metabolism of Verapamil caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[37]
Budesonide	DMJIBAW	Moderate	Decreased metabolism of Verapamil caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[39]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Verapamil caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[40]
Roflumilast	DMPGHY8	Moderate	Decreased metabolism of Verapamil caused by Roflumilast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[37]
Zileuton	DMVRIC2	Minor	Decreased metabolism of Verapamil caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[41]
Desipramine	DMT2FDC	Moderate	Decreased metabolism of Verapamil caused by Desipramine mediated inhibition of CYP450 enzyme.	Attention deficit hyperactivity disorder [6A05]	[42]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Verapamil caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[43]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Verapamil caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[44]
Ceftriaxone	DMCEW64	Moderate	Increased plasma concentration of Verapamil and Ceftriaxone due to competitive binding of plasma proteins.	Bacterial infection [1A00-1C4Z]	[32]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Verapamil caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[45]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Verapamil caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[46]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Verapamil caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[47]
Loperamide	DMOJZQ9	Major	Decreased clearance of Verapamil due to the transporter inhibition by Loperamide.	Bowel habit change [ME05]	[48]
Talazoparib	DM1KS78	Major	Decreased clearance of Verapamil due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[37]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Verapamil caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[49]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Verapamil caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[50]
HKI-272	DM6QOVN	Major	Decreased metabolism of Verapamil caused by HKI-272 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[51]
LY2835219	DM93VBZ	Moderate	Decreased metabolism of Verapamil caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[52]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Verapamil caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[53]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Verapamil caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Verapamil caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[54]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Verapamil caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[55]
Bosutinib	DMTI8YE	Major	Decreased metabolism of Verapamil caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[56]
Atorvastatin	DMF28YC	Moderate	Decreased metabolism of Verapamil caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[57]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Verapamil caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[58]
PF-04449913	DMSB068	Moderate	Decreased metabolism of Verapamil caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[59]
Indacaterol	DMQJHR7	Minor	Decreased metabolism of Verapamil caused by Indacaterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[60]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Verapamil due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[61]
Irinotecan	DMP6SC2	Moderate	Decreased metabolism of Verapamil caused by Irinotecan mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[31]
Intedanib	DMSTA36	Moderate	Decreased metabolism of Verapamil caused by Intedanib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[62]
Ulipristal	DMBNI20	Minor	Decreased metabolism of Verapamil caused by Ulipristal mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[37]
Alfentanil	DMVO0UB	Major	Decreased metabolism of Verapamil caused by Alfentanil mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[63]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Verapamil caused by Oxtriphylline mediated inhibition of CYP450 enzyme.	Cough [MD12]	[40]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Verapamil caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[64]
Pasireotide	DMHM7JS	Moderate	Increased risk of bradycardia by the combination of Verapamil and Pasireotide.	Cushing syndrome [5A70]	[31]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Verapamil caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[37]
Ivacaftor	DMZC1HS	Major	Decreased metabolism of Verapamil caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[37]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Verapamil caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[65]
Rivaroxaban	DMQMBZ1	Moderate	Decreased metabolism of Verapamil caused by Rivaroxaban mediated inhibition of CYP450 enzyme.	Deep vein thrombosis [BD71]	[66]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Verapamil caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[67]
Trimipramine	DM1SC8M	Moderate	Decreased metabolism of Verapamil caused by Trimipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[42]
Vilazodone	DM4LECQ	Moderate	Decreased metabolism of Verapamil caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[68]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Verapamil caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[69]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Verapamil and Selegiline.	Depression [6A70-6A7Z]	[70]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Verapamil and Isocarboxazid.	Depression [6A70-6A7Z]	[70]
Escitalopram	DMFK9HG	Minor	Decreased metabolism of Verapamil caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[71]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Verapamil and Tranylcypromine.	Depression [6A70-6A7Z]	[70]
OPC-34712	DMHG57U	Major	Decreased metabolism of Verapamil caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[72]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Verapamil and Phenelzine.	Depression [6A70-6A7Z]	[70]
Clomipramine	DMINRKW	Moderate	Decreased metabolism of Verapamil caused by Clomipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[42]
Doxepin	DMPI98T	Moderate	Decreased metabolism of Verapamil caused by Doxepin mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[42]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Verapamil caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[73]
Zonisamide	DM0DTF7	Moderate	Decreased metabolism of Verapamil caused by Zonisamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[74]
Primidone	DM0WX6I	Moderate	Increased metabolism of Verapamil caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[75]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Verapamil caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[76]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Verapamil caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Verapamil caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[77]
Ethotoin	DMXWOCP	Moderate	Increased plasma concentrations of Verapamil and Ethotoin due to competitive inhibition of the same metabolic pathway.	Epilepsy/seizure [8A61-8A6Z]	[77]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Verapamil caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[75]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Verapamil caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[37]
Nadolol	DMW6GVL	Major	Increased risk of cardiac depression by the combination of Verapamil and Nadolol.	Essential hypertension [BA00]	[30]
Dantrolene	DM1D8XY	Moderate	Increased risk of hyperkalemia by the combination of Verapamil and Dantrolene.	Fever [MG26]	[78]
Bay 80-6946	DMLOS5R	Moderate	Decreased metabolism of Verapamil caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[79]
Tazemetostat	DMWP1BH	Major	Decreased metabolism of Verapamil caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[80]
Solifenacin	DMG592Q	Moderate	Decreased metabolism of Verapamil caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[81]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Verapamil caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[82]
Tolterodine	DMSHPW8	Moderate	Decreased metabolism of Verapamil caused by Tolterodine mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[83]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Verapamil caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[84]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Verapamil caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[84]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Verapamil caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[56]
Avapritinib	DMK2GZX	Major	Decreased metabolism of Verapamil caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[37]
Metipranolol	DMJMVKI	Major	Increased risk of cardiac depression by the combination of Verapamil and Metipranolol.	Glaucoma [9C61]	[85]
Levobetaxolol	DMSREPX	Major	Increased risk of cardiac depression by the combination of Verapamil and Levobetaxolol.	Glaucoma [9C61]	[85]
Levobunolol	DMTNFCQ	Major	Increased risk of cardiac depression by the combination of Verapamil and Levobunolol.	Glaucoma [9C61]	[85]
Colchicine	DM2POTE	Major	Decreased metabolism of Verapamil caused by Colchicine mediated inhibition of CYP450 enzyme.	Gout [FA25]	[86]
Ergotamine	DMKR3C5	Moderate	Decreased metabolism of Verapamil caused by Ergotamine mediated inhibition of CYP450 enzyme.	Headache [8A80-8A84]	[87]
Eplerenone	DMF0NQR	Major	Decreased metabolism of Verapamil caused by Eplerenone mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[88]
Carvedilol	DMHTEAO	Major	Increased risk of cardiac depression by the combination of Verapamil and Carvedilol.	Heart failure [BD10-BD1Z]	[30]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Verapamil caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[89]
Simeprevir	DMLUA9D	Moderate	Decreased clearance of Verapamil due to the transporter inhibition by Simeprevir.	Hepatitis virus infection [1E50-1E51]	[90]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Verapamil caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[89]
Daclatasvir	DMSFK9V	Moderate	Decreased metabolism of Verapamil caused by Daclatasvir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[56]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Verapamil caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[91]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Verapamil caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[92]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Verapamil and Procarbazine.	Hodgkin lymphoma [2B30]	[70]
MK-1439	DM215WE	Minor	Decreased metabolism of Verapamil caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[93]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Verapamil caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[94]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Verapamil caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[95]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Verapamil caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[96]
Tipranavir	DM8HJX6	Moderate	Accelerated clearance of Verapamil due to the transporter induction by Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[97]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Verapamil caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[98]
Rilpivirine	DMJ0QOW	Moderate	Decreased metabolism of Verapamil caused by Rilpivirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Verapamil caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[95]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Verapamil caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[99]
Maraviroc	DMTL94F	Moderate	Decreased clearance of Verapamil due to the transporter inhibition by Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[100]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Verapamil caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[56]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Verapamil caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[101]
Tolvaptan	DMIWFRL	Moderate	Decreased metabolism of Verapamil caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[102]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Verapamil caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[103]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Verapamil due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[104]
Suvorexant	DM0E6S3	Major	Decreased metabolism of Verapamil caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[105]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Verapamil caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[75]
Ramelteon	DM7IW9J	Moderate	Decreased metabolism of Verapamil caused by Ramelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[106]
Triazolam	DMETYK5	Moderate	Decreased metabolism of Verapamil caused by Triazolam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[107]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Verapamil and Propiomazine.	Insomnia [7A00-7A0Z]	[108]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Verapamil caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[109]
ITI-007	DMUQ1DO	Major	Decreased metabolism of Verapamil caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[110]
Naloxegol	DML0B41	Major	Decreased metabolism of Verapamil caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[37]
Pemigatinib	DM819JF	Major	Decreased metabolism of Verapamil caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[37]
Brigatinib	DM7W94S	Major	Decreased metabolism of Verapamil caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[56]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Verapamil caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[111]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Verapamil caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[112]
Osimertinib	DMRJLAT	Moderate	Decreased metabolism of Verapamil caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[113]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Verapamil caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[114]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Verapamil due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[115]
Selpercatinib	DMZR15V	Major	Decreased metabolism of Verapamil caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[37]
Halofantrine	DMOMK1V	Major	Decreased metabolism of Verapamil caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[116]
Hydroxychloroquine	DMSIVND	Moderate	Decreased metabolism of Verapamil caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[56]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Verapamil caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[117]
GDC-0199	DMH0QKA	Major	Decreased metabolism of Verapamil caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[56]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Verapamil caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[118]
Acalabrutinib	DM7GCVW	Major	Decreased metabolism of Verapamil caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[119]
Ibrutinib	DMHZCPO	Major	Decreased metabolism of Verapamil caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[120]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Verapamil due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[56]
Vemurafenib	DM62UG5	Minor	Decreased metabolism of Verapamil caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[56]
Selumetinib	DMC7W6R	Major	Decreased metabolism of Verapamil caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[121]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Verapamil caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[37]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Verapamil caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[122]
Almogran	DM7I64Z	Minor	Decreased metabolism of Verapamil caused by Almogran mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[123]
Rimegepant	DMHOAUG	Moderate	Decreased metabolism of Verapamil caused by Rimegepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[124]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Verapamil caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[125]
Flibanserin	DM70DTN	Major	Decreased metabolism of Verapamil caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[126]
Midazolam	DMXOELT	Moderate	Decreased metabolism of Verapamil caused by Midazolam mediated inhibition of CYP450 enzyme.	Mood/affect symptom [MB24]	[107]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Verapamil caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[127]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Verapamil and Thalidomide.	Multiple myeloma [2A83]	[56]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Verapamil and Siponimod.	Multiple sclerosis [8A40]	[56]
Fingolimod	DM5JVAN	Major	Increased risk of bradycardia by the combination of Verapamil and Fingolimod.	Multiple sclerosis [8A40]	[128]
Ozanimod	DMT6AM2	Moderate	Increased risk of bradycardia by the combination of Verapamil and Ozanimod.	Multiple sclerosis [8A40]	[129]
Romidepsin	DMT5GNL	Moderate	Decreased clearance of Verapamil due to the transporter inhibition by Romidepsin.	Mycosis fungoides [2B01]	[130]
Fedratinib	DM4ZBK6	Minor	Decreased metabolism of Verapamil caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[37]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Verapamil caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[131]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Verapamil caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[37]
Modafinil	DMYILBE	Moderate	Increased metabolism of Verapamil caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[56]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Verapamil and Promethazine.	Nausea/vomiting [MD90]	[108]
Entrectinib	DMMPTLH	Major	Decreased metabolism of Verapamil caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[56]
Sibutramine	DMFJTDI	Minor	Decreased metabolism of Verapamil caused by Sibutramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[132]
Levomethadyl Acetate	DM06HG5	Major	Decreased metabolism of Verapamil caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[133]
MK-4827	DMLYGH4	Moderate	Decreased clearance of Verapamil due to the transporter inhibition by MK-4827.	Ovarian cancer [2C73]	[134]
Buprenorphine	DMPRI8G	Moderate	Decreased metabolism of Verapamil caused by Buprenorphine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[135]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Verapamil and Safinamide.	Parkinsonism [8A00]	[70]
Istradefylline	DM20VSK	Moderate	Decreased metabolism of Verapamil caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[136]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Verapamil and Rasagiline.	Parkinsonism [8A00]	[70]
Pimavanserin	DMR7IVC	Moderate	Decreased metabolism of Verapamil caused by Pimavanserin mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[137]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Verapamil caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[138]
Lefamulin	DME6G97	Major	Decreased metabolism of Verapamil caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[139]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Verapamil caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[140]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Verapamil caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[141]
Enzalutamide	DMGL19D	Moderate	Decreased metabolism of Verapamil caused by Enzalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[142]
Relugolix	DMK7IWL	Major	Decreased clearance of Verapamil due to the transporter inhibition by Relugolix.	Prostate cancer [2C82]	[143]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Verapamil caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[144]
Tamsulosin	DM5QF9V	Moderate	Decreased metabolism of Verapamil caused by Tamsulosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[145]
Dutasteride	DMQ4TJK	Moderate	Decreased metabolism of Verapamil caused by Dutasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[146]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Verapamil and Levomepromazine.	Psychotic disorder [6A20-6A25]	[108]
Riociguat	DMXBLMP	Moderate	Decreased metabolism of Verapamil caused by Riociguat mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[56]
Everolimus	DM8X2EH	Major	Decreased metabolism of Verapamil caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[147]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Verapamil caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[37]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Verapamil caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[148]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of Verapamil caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[149]
Tofacitinib	DMBS370	Moderate	Decreased metabolism of Verapamil caused by Tofacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[56]
Quetiapine	DM1N62C	Moderate	Decreased metabolism of Verapamil caused by Quetiapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[150]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Verapamil and Mesoridazine.	Schizophrenia [6A20]	[108]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Verapamil and Thioridazine.	Schizophrenia [6A20]	[108]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Verapamil and Iloperidone.	Schizophrenia [6A20]	[108]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Verapamil and Paliperidone.	Schizophrenia [6A20]	[108]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Verapamil and Perphenazine.	Schizophrenia [6A20]	[108]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Verapamil and Molindone.	Schizophrenia [6A20]	[108]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Verapamil and Thiothixene.	Schizophrenia [6A20]	[108]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Verapamil and Trifluoperazine.	Schizophrenia [6A20]	[108]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Verapamil and Risperidone.	Schizophrenia [6A20]	[108]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Verapamil and Amisulpride.	Schizophrenia [6A20]	[37]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Verapamil and Asenapine.	Schizophrenia [6A20]	[108]
Fentanyl	DM8WAHT	Major	Decreased metabolism of Verapamil caused by Fentanyl mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[56]
Avanafil	DM75CXN	Major	Decreased metabolism of Verapamil caused by Avanafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[151]
Tadalafil	DMJZHT1	Moderate	Decreased metabolism of Verapamil caused by Tadalafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[152]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Verapamil caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[153]
LDE225	DMM9F25	Major	Decreased metabolism of Verapamil caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[154]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Verapamil caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[37]
Larotrectinib	DM26CQR	Moderate	Decreased clearance of Verapamil due to the transporter inhibition by Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[56]
Docetaxel	DMDI269	Major	Decreased metabolism of Verapamil caused by Docetaxel mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[155]
Trabectedin	DMG3Y89	Moderate	Decreased metabolism of Verapamil caused by Trabectedin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[37]
Armodafinil	DMGB035	Moderate	Increased metabolism of Verapamil caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[56]
LEE011	DMMX75K	Moderate	Decreased metabolism of Verapamil caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[56]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Verapamil caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[156]
Doxorubicin	DMVP5YE	Moderate	Interference of cell/tissue uptake of Verapamil by Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[157]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Verapamil caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[37]
Pomalidomide	DMTGBAX	Moderate	Decreased clearance of Verapamil due to the transporter inhibition by Pomalidomide.	Systemic sclerosis [4A42]	[56]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Verapamil caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[158]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Verapamil due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[159]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Verapamil caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[37]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Verapamil caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[37]
Cabozantinib	DMIYDT4	Moderate	Decreased metabolism of Verapamil caused by Cabozantinib mediated inhibition of CYP450 enzyme.	Thyroid cancer [2D10]	[160]
Tizanidine	DMR2IQ4	Major	Decreased metabolism of Verapamil caused by Tizanidine mediated inhibition of CYP450 enzyme.	Tonus and reflex abnormality [MB47]	[161]
Tacrolimus	DMZ7XNQ	Moderate	Decreased metabolism of Verapamil caused by Tacrolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[162]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Verapamil caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[37]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Verapamil and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[108]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Verapamil and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[163]
Fluticasone	DMGCSVF	Moderate	Decreased metabolism of Verapamil caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[56]
Amiodarone	DMUTEX3	Major	Increased risk of bradycardia by the combination of Verapamil and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[164]
-----------


⏷ Show the Full List of 216 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 30	E00456	3000709	Colorant
D&C red no. 33	E00261	19116	Colorant
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Fumaric acid	E00420	444972	Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
methylparaben	E00149	7456	Antimicrobial preservative
Oleic acid	E00421	445639	Emulsifying agent; Penetration agent; Solubilizing agent
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dibutyl sebacate	E00160	7986	Plasticizing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate	E00671	Not Available	Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 40 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Verapamil 200 mg capsule	200 mg	24 HR Extended Release Oral Capsule	Oral
Verapamil 100 mg capsule	100 mg	24 HR Extended Release Oral Capsule	Oral
Verapamil 300 mg capsule	300 mg	24 HR Extended Release Oral Capsule	Oral
Verapamil 240 mg capsule	240 mg	24 HR Extended Release Oral Capsule	Oral
Verapamil 120 mg capsule	120 mg	24 HR Extended Release Oral Capsule	Oral
Verapamil 180 mg capsule	180 mg	24 HR Extended Release Oral Capsule	Oral
Verapamil 360 mg capsule	360 mg	24 HR Extended Release Oral Capsule	Oral
Verapamil 120 mg capsule	120 mg	24 HR Extended Release Capsule	Oral
Verapamil 180 mg tablet	180 mg	24 HR Extended Release Oral Tablet	Oral
Verapamil 240 mg tablet	240 mg	24 HR Extended Release Oral Tablet	Oral
Verapamil 120 mg tablet	120 mg	Extended Release Oral Tablet	Oral
Verapamil 180 mg tablet	180 mg	Extended Release Oral Tablet	Oral
Verapamil 240 mg tablet	240 mg	Extended Release Oral Tablet	Oral
Verapamil 40 mg tablet	40 mg	Oral Tablet	Oral
Verapamil 120 mg tablet	120 mg	Oral Tablet	Oral
Verapamil 80 mg tablet	80 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Verapamil FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2406).
3	ClinicalTrials.gov (NCT04351763) Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms. U.S. National Institutes of Health.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7	Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
8	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
9	MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
10	Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
11	Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
12	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
13	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
14	Improved expression and purification of human multidrug resistance protein MDR1 from baculovirus-infected insect cells. Protein Expr Purif. 2009 Jul;66(1):7-14.
15	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
16	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
17	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
18	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
19	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
20	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
21	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
22	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
23	Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. doi: 10.1161/01.cir.97.13.1227.
24	Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
25	Multidrug resistance protein-6 (MRP6) in human dermal fibroblasts. Comparison between cells from normal subjects and from Pseudoxanthoma elasticum patients. Matrix Biol. 2003 Nov;22(6):491-500. doi: 10.1016/j.matbio.2003.09.001.
26	Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?. Biochem Pharmacol. 2004 Aug 15;68(4):783-90. doi: 10.1016/j.bcp.2004.05.006.
27	A common 1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol. 2012 Jan 3;59(1):49-56. doi: 10.1016/j.jacc.2011.08.061.
28	KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics. 2007 Sep;17(9):719-29. doi: 10.1097/FPC.0b013e32810f2e3c.
29	Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiol Genomics. 2002 Oct 29;11(2):45-52. doi: 10.1152/physiolgenomics.00064.2002.
30	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
31	Canadian Pharmacists Association.
32	Kishore K, Raina A, Misra V, Jonas E "Acute verapamil toxicity in a patient with chronic toxicity: possible interaction with ceftriaxone and clindamycin." Ann Pharmacother 27 (1993): 877-80. [PMID: 8364267]
33	Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
34	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
35	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
36	Multum Information Services, Inc. Expert Review Panel.
37	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38	Bailey DG, Dresser GK "Natural products and adverse drug interactions." Can Med Assoc J 170 (2004): 1531-2. [PMID: 15136542]
39	Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
40	Abernethy DR, Egan JM, Dickinson TH, Carrum G "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans." J Pharmacol Exp Ther 244 (1988): 994-9. [PMID: 3252045]
41	Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
42	Hermann DJ, Krol TF, Dukes GE, et al "Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine." J Clin Pharmacol 32 (1992): 176-83. [PMID: 1613128]
43	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
44	Goldschmidt N, Azaz-Livshits T, Gotsman, Nir-Paz R, Ben-Yehuda A, Muszkat M "Compound cardiac toxicity of oral erythromycin and verapamil." Ann Pharmacother 35 (2001): 1396-9. [PMID: 11724091]
45	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
46	Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
47	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
48	Adachi Y, Suzuki H, Sugiyama Y "Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in Situ and in Vivo." Pharm Res 20 (2003): 1163-9. [PMID: 12948013]
49	Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
50	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
51	Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
52	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
53	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
54	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
55	Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
56	Cerner Multum, Inc. "Australian Product Information.".
57	Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
58	Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
59	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
61	Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
62	Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
63	Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
64	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
65	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
66	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
67	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
68	Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
69	Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
70	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
71	Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
72	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
73	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
74	Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
75	Rutledge DR, Pieper JA, Mirvis DM "Effects of chronic phenobarbital on verapamil dispostion in humans." J Pharmacol Exp Ther 246 (1988): 7-13. [PMID: 3392664]
76	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
77	Hedman A, Angelin B, Arvidsson A, et al "Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans." Clin Pharmacol Ther 49 (1991): 256-62. [PMID: 2007320]
78	Rubin AS, Zablocki AD "Hyperkalemia, verapamil, and dantrolene." Anesthesiology 66 (1987): 246-9. [PMID: 3813090]
79	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
80	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
81	Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
82	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
83	Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
84	Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
85	Packer M "Combined beta-adrenergic and calcium-entry blockage in angina pectoris." N Engl J Med 320 (1989): 709-18. [PMID: 2564164]
86	Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
87	Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
88	Product Information. Inspra (eplerenone). Searle, Chicago, IL.
89	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
90	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
91	Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
92	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
93	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
94	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
95	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
96	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
97	Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
98	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
99	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
100	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
101	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
102	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
103	Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
104	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
105	Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
106	Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
107	Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ "Dose of midazolam should be reduced during diltiazem and verapamil treatments." Br J Clin Pharmacol 37 (1994): 221-5. [PMID: 8198928]
108	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
109	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
110	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
111	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
112	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
113	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
114	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
115	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
116	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
117	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
118	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
119	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
120	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
121	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
122	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
123	Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
124	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
125	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
126	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
127	Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
128	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
129	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
130	Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
131	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
132	Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
133	Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
134	Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
135	Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
136	Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
137	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
138	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
139	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
140	Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
141	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
142	Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
143	Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
144	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
145	Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
146	Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
147	Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
148	Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
149	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
150	DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
151	Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
152	Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
153	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
154	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
155	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
156	Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
157	Li W, Zhang H, Assaraf YG, et al. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.?Drug Resist Updat. 2016;27:14-29. [PMID: 27449595]
158	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
159	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
160	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
161	Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]
162	Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161]
163	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
164	Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]